FDA adds warning to BMS leukemia drug

Bristol-Myers Squibb's ($BMY) leukemia treatment Sprycel has a new warning. In a new safety announcement, the FDA said the drug can increase the risk of pulmonary arterial hypertension (PAH). The potential risk has been added to the warnings and precautions section of Sprycel's label.

Cases of PAH were identified by BMS's database of adverse-event reports, which the company uses to track potential side effects. The 12 Sprycel patients who developed PAH were also taking other drugs, the agency said, or had preexisting conditions that might have helped spur development of PAH. But Sprycel was the most likely cause in these 12 cases, the agency said. More than 30,000 patients worldwide have used the drug since it was approved in 2006.

Doctors should evaluate patients for potential cardiopulmonary disease before they begin therapy with Sprycel and should be monitored during treatment. The PAH problem could be reversible with cessation of Sprycel treatment, the FDA said.

- check out the FDA announcement
- see the Dow Jones story
- get more from Bloomberg

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.